CClinicalTrials.gg
Not yet recruitingNCT07398430OSA-ACS-MetUpdated Feb 9, 2026

Metabolic Characteristics and Prognostic Model of Acute Coronary Syndrome Complicated With Obstructive Sleep Apnea

An observational study in Sleep Disordered Breathing (SDB), sponsored by Beijing Hospital. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Beijing Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Obstructive sleep apnea (OSA) significantly increases the risk of cardiovascular events in patients with acute coronary syndrome (ACS), yet the underlying metabolic mechanisms remain unclear. This study aims to analyze the metabolic characteristics of ACS patients with OSA using metabolomics based on a prospective cohort. The study intends to construct an artificial intelligence-based risk stratification model to improve prognosis prediction and facilitate precision medicine for this population.

02

Conditions studied

  • Sleep Disordered Breathing (SDB)
03

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospitalized patients diagnosed with ACS at Beijing Hospital.

Inclusion criteria

  • Age 18-85 years.
  • Diagnosed with ACS, including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina.
  • Willing to participate and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock or cardiac arrest.
  • Central sleep apnea or other types of sleep disordered breathing.
  • Previous or current treatment with continuous positive airway pressure.
  • Inability to complete polysomnography or invalid data.
  • Malignancy or life expectancy \< 1 year.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • OtherBiological Sample Collection

    Collection of blood, urine, and stool samples for metabolomics analysis.

05

What researchers measure

Primary outcomes

  1. Incidence of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Time frame: 12 Months

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07398430
Lead sponsor
Beijing Hospital
Responsible party
WeiGong (Deputy Director, Beijing Hospital) — Principal investigator
First posted
Feb 9, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 9, 2026

Study contacts

Wei Gong
Contact
gongwei5180@bjhmoh.cn
+86 13717676086

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion